Empowered patients make informed choices and are likelier to adhere to their weight loss plans
The mechanistic and early clinical data are promising but not definitive
Does taking a GLP-1 mean you are taking the easy way out? or triggering an eating disorder
The study just published in Thyroid was a multisite cohort study with subsequent meta-analysis which included six population-based databases from Canada (Ontario), Denmark, Norway, South Korea, Sweden, and Taiwan (11)
For patients with first-time anti-obesity medication prescriptions in March 2025, only 46.8% had evidence of a prescription fill within 60 days, compared to 72.2% of patients receiving anti-diabetic medication prescriptions
Semaglutide: The one that started it all (sort of) Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1)